Special Issue

Metabolomics Biomarkers for Rehabilitation Outcomes in Neurodegenerative Diseases

Message from the Guest Editors

The principal topic of this Special Issue is to explore the impact of fluid biomarkers, and proteomic and metabolomic profiles, as indicators predicting outcome or individuating specific treatment needs during the rehabilitation of patients with neurodegenerative diseases. The identification of biomarkers, as well as the investigation of proteomic and metabolomic profiling in order to highlight the specific treatment response of patients who have survived stroke or are suffering from a chronic neurological disorder, is currently one of the major topics in neurodegenerative diseases. Indeed. based on their detection, the fluid biomarkers are objectively measurable and evaluable potential indicators predicting not only the disease progression, but also both pharmacological and nonpharmacological treatment responses. Similarly, the examination of specific assays recently provided a metabolomic signature highly predictive of Parkinson's disease and Alzheimer's disease.

Guest Editors

Dr. Paolo Bongioanni


Dr. Renata Del Carratore

Dr. Andrea Diana

Dr. Cristina Dolciotti

Deadline for manuscript submissions

closed (31 May 2024)



an Open Access Journal by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



mdpi.com/si/169083

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/metabolites





Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).

